

Today, poor solubility of New Chemical Entities is one of the most frequent and greatest challenges for formulators in the development of oral solid dosage forms. Improving API solubilization is thus of interest to increase bioavailability.




Discover our bioavailability enhancers for poorly-soluble drugs to improve drug release






- All components compliant with the current EP & USP/NF

What is it? Microencapsulated solubilizer for oral solid dosage applications forms



How does it work?



Microencapsulated solubilizer can be used to help...

... Formulator

... Patient



- Easy to use: simple mixing with other powders
- Gain time & cost: it cuts out process steps in comparison with wet granulation
- Avoid granulation for moisture sensitive APIs
- Avoid the degradation of the API without impacting the tablet properties
- Dosage forms: Tablets by direct compression, capsules, dry syrups, dry suspensions



Development of new drugs or dosage forms from poorly-soluble API



Improve drug product efficacy by improving API bioavailability



Approved with various API: Arthemether + Lumefantrine, Nebivolol, Atorvastatin, Rivaroxaban, Ledipasvir, Albendazole, Simvastatin, Loratidine, Glimepiride'

* Non exhaustive list. Request sales team for list of countries approvals.



Contact us to ask for a sample or for any questions seppic.excipients@airliquide.com







